Exact Sciences (NASDAQ:EXAS) PT Raised to $50.00 at Piper Sandler

Exact Sciences (NASDAQ:EXASGet Rating) had its target price boosted by equities research analysts at Piper Sandler from $40.00 to $50.00 in a report released on Monday, The Fly reports. The firm presently has a “neutral” rating on the medical research company’s stock. Piper Sandler’s price target would suggest a potential upside of 12.92% from the stock’s previous close.

Several other research analysts also recently issued reports on the stock. Citigroup lowered their price target on shares of Exact Sciences from $50.00 to $35.00 in a report on Friday, November 4th. Cowen lowered their price target on shares of Exact Sciences from $83.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday, August 3rd. Craig Hallum cut shares of Exact Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $60.00 to $35.00 in a research note on Wednesday, October 19th. Benchmark reduced their price objective on shares of Exact Sciences to $54.00 in a research note on Tuesday, August 9th. Finally, StockNews.com started coverage on shares of Exact Sciences in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $64.86.

Exact Sciences Trading Down 1.2 %

Shares of EXAS stock opened at $44.28 on Monday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.72. The stock has a market cap of $7.87 billion, a P/E ratio of -10.80 and a beta of 1.31. The stock has a 50 day simple moving average of $36.06 and a 200 day simple moving average of $41.83. Exact Sciences has a 1 year low of $29.27 and a 1 year high of $92.75.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, insider Everett Cunningham sold 16,872 shares of the stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of $31.37, for a total value of $529,274.64. Following the completion of the sale, the insider now owns 18,654 shares in the company, valued at approximately $585,175.98. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

Several large investors have recently modified their holdings of EXAS. Armistice Capital LLC purchased a new stake in shares of Exact Sciences during the 3rd quarter worth approximately $50,684,000. Capital World Investors increased its stake in shares of Exact Sciences by 17.2% during the 1st quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock worth $383,652,000 after purchasing an additional 804,159 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Exact Sciences by 12.2% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,517,145 shares of the medical research company’s stock worth $211,742,000 after buying an additional 709,540 shares during the period. Vanguard Group Inc. boosted its holdings in Exact Sciences by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock worth $541,823,000 after buying an additional 698,740 shares during the period. Finally, ARK Investment Management LLC boosted its holdings in Exact Sciences by 4.5% in the 2nd quarter. ARK Investment Management LLC now owns 14,971,765 shares of the medical research company’s stock worth $745,744,000 after buying an additional 647,803 shares during the period. Hedge funds and other institutional investors own 90.95% of the company’s stock.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Articles

The Fly logo

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.